[1]Vandamme D, Landuyt B, Luyten W, et prehensive summary of LL37, the factotum human cathelicidin peptide[J].Cell Immunol, 2020, 280 (1) :2235. [2]Greer A, Zenobia C, Darveau and LL37:a review of function in the gingival epithelium[J].Periodontol, 2020, 63 (1) :6779. [3]盧志陽, 楊磊, 高艷彬, 等。人源抗菌肽LL37對鮑曼不動桿菌感染大鼠創(chuàng)面的抗菌作用[J].廣東醫(yī)學(xué), 2020, 36 (6) :843845. [4]楊新艷, 張挪富, 謝佳星, 等。急性肺損傷小鼠肺組織抗菌肽的表達(dá)[J].廣東醫(yī)學(xué), 2020, 34 (22) :33863388. [5]Xhindoli D, Pacor S, Benincasa M, et human cathelicidin LL37A poreforming antibacterial peptide and hostcell modulator[J].Biochim Biophys Acta, 2020, 1858 (3) :54666. [6]Piktel E, Niemirowicz K, Wnorowska U, et Role of Cathelicidin LL37 in Cancer Development[J].Arch Immunol Ther Exp, 2020, 64 (1) :3346. [7]Svensson D, Nebel D, Nilsson D3 modulates the innate immune response through regulation of the hCAP18/LL37 gene expression and cytokine production[J].Inflamm Res, 2020, 65 (1) :2532.